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Abstract 
Objective: To examine anti-microbial prescribing practices associated with ventilator-associated 
pneumonia from data gathered during an audit of practice and outcomes in intensive care units (ICUs) in 
a previously published study. Results: The patient sample of 169 was 65% male with an average age of 
59.7 years, a mean APACHE II score of 20.6, and a median ICU stay of 11 days. While ventilator-
associated pneumonia was identified using a specific 4-item checklist in 29 patients, agreement between 
the checklist and independent physician diagnosis was only 17%. Sputum microbe culture reporting was 
sparse. Approximately 75% of the sample was administered an antimicrobial (main indications: lung 
infection [54%] and prophylaxis [11%]). No clinical justification was documented for 20% of prescriptions. 
Piperacillin/tazobactam was most frequently prescribed (1/3rd of all antimicrobial prescriptions) with 
about half of those for prophylaxis. Variations in prescribing practices were identified, including apparent 
gaps in antimicrobial stewardship; particularly in relation to prescribing for prophylaxis and therapy de-
escalation. Sputum microbe culture reports for VAP did not appear to contribute to prescribing decisions 
but physician suspicion of lung infection and empiric therapy rather than ventilator-associated pneumonia 
criteria and guideline concordance. 
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Antimicrobial prescription patterns 
and ventilator associated pneumonia: findings 
from a 10-site prospective audit
Rosalind M. Elliott1,2* , Anthony R. Burrell1, Peter W. Harrigan3, Margherita Murgo4,5, Kaye D. Rolls5,6,9,10, 
David W. Sibbritt1, Jonathan R. Iredell7,8 and Doug Elliott1
Abstract 
Objective: To examine anti-microbial prescribing practices associated with ventilator-associated pneumonia from 
data gathered during an audit of practice and outcomes in intensive care units (ICUs) in a previously published study.
Results: The patient sample of 169 was 65% male with an average age of 59.7 years, a mean APACHE II score of 20.6, 
and a median ICU stay of 11 days. While ventilator-associated pneumonia was identified using a specific 4-item check-
list in 29 patients, agreement between the checklist and independent physician diagnosis was only 17%. Sputum 
microbe culture reporting was sparse. Approximately 75% of the sample was administered an antimicrobial (main 
indications: lung infection [54%] and prophylaxis [11%]). No clinical justification was documented for 20% of prescrip-
tions. Piperacillin/tazobactam was most frequently prescribed (1/3rd of all antimicrobial prescriptions) with about half 
of those for prophylaxis. Variations in prescribing practices were identified, including apparent gaps in antimicrobial 
stewardship; particularly in relation to prescribing for prophylaxis and therapy de-escalation. Sputum microbe culture 
reports for VAP did not appear to contribute to prescribing decisions but physician suspicion of lung infection and 
empiric therapy rather than ventilator-associated pneumonia criteria and guideline concordance.
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Introduction
Reducing hospital-acquired infection is an important 
goal in improving quality of care and decreasing iat-
rogenic events for patients in hospital. Importantly, 
consistent and systematic information about ventilator-
associated pneumonia-related (VAP) pathogens and 
associated antimicrobial prescribing practices in Aus-
tralasian intensive care units (ICUs) is scarce. There are 
however some commonalities in pathogen types and 
prescribing patterns available from the international lit-
erature. Reports from Europe and North America suggest 
that microbes such as Acinetobacter baumannii, Staphy-
lococcus aureus and members of the Enterobacteriaceae 
and Pseudomonas families are commonly associated with 
VAP [1]. Patterns of infection may vary over time and 
changes appear to be associated with antimicrobial use. 
For example, one European centre noted increased Enter-
obacteriaceae isolation rates (suggested by the authors to 
be related to antibiotic use), but unchanged S. aureus and 
Pseudomonas aeruginosa rates over a 5 years period [1].
Internationally, antimicrobial prescription rates are 
high in critical care, with prescriptions for VAP largely 
compliant with practice guidelines [2, 3]. Nevertheless 
some common areas have been identified for practice 
improvement in antimicrobial stewardship, including the 
use of culture-sensitive empiric therapy and appropriate 
de-escalation of therapy [4].
Given this context of an increasing incidence if antimi-
crobial resistance and recognition of the negative impact 
of hospital acquired infections, our aim was to develop a 
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surveillance checklist for identification/screening of VAP 
and conduct an audit in a sample of ICUs in Australia 
and New Zealand to estimate the incidence of VAP. Audit 
data collected included antimicrobials prescribed and 
reports of microbial isolates in this cohort of mechani-
cally ventilated patients.
The purpose of this brief research report is therefore 
to present previously unpublished data on antimicrobial 
prescription practices and offer our understanding of 
these practices in a sample of ICUs.
Main text
Methods
A prospective 30-day audit on clinical surveillance of 
VAP in 10 ICUs (9 in Australia, 1 in New Zealand) was 
conducted; 7 were tertiary referral units [5]. A more 
detailed report of the methods of the parent study was 
previously published [6]. Briefly, invitations to participate 
in the study were provided through mail distribution lists 
to Australian and New Zealand Intensive Care Society 
(ANZICS) members, with expressions of interest to par-
ticipate received from medical directors of ICUs. Follow-
ing institutional Review Board approval for each clinical 
site ICU-based research coordinators collected audit data 
for all patients: aged > 16  years; and mechanically venti-
lated (MV) for > 72 h.
Baseline data included age, gender, and diagnosis (at 
ICU admission). At or after 72  h of MV, data were col-
lected daily using a case report form including a spe-
cific VAP checklist (decreasing gas exchange, sputum 
changes, chest X-ray infiltrates, inflammatory response; 
Table  1), reports of sputum collection for laboratory 
analysis (when ordered), microbes colonised (presence 
of microbes in the absence of disease)/grown (fungus, 
bacteria or virus) taken from microbiology laboratory 
reports, antimicrobial prescriptions for up to four medi-
cations each day, and independent ICU physician (inten-
sivist) reports of VAP and infections, until ICU discharge. 
Day 30 survival outcome while in hospital was also 
recorded. A web-based database was used for data entry 
at each site. Descriptive data analysis is reported, using 
frequencies and proportions.
Results
The demographic and clinical characteristics of the final 
sample of 169 patients are described in Table  2, along 
with a summary of VAP identification using the check-
list and independent physician diagnosis, sputum find-
ings and antimicrobial prescribing activities. There was a 
mean of eight data collection days per patient.
Of note, antimicrobial agents were prescribed in the 
absence of abnormal sputum findings for 73% of the 
data collection days. For VAP cases identified using the 
screening checklist, antimicrobials were prescribed for 
83% of patients, despite limited reporting of colonised 
or infected sputum (from microbiology reports). Pipera-
cillin/tazobactam comprised 32% of antimicrobial pre-
scriptions. The main prophylaxis antimicrobials were 
cefazolin (12 patients, mean 3  days), and piperacillin/
tazobactam (10 patients, mean 3 days); acyclovir was also 
prescribed (6 patients, mean 4 days). No agents were pre-
scribed simultaneously.
Discussion
Three key findings are noted from this microbial-
focused report of the audit: (1) sputum collection for 
microbiological culture and sensitivity testing were 
rarely requested, and appeared irrelevant for prescrib-
ing practices in this sample; (2) antibiotics appeared 
to be commonly prescribed for prophylaxis; and (3) 
Table 1 Ventilator associated pneumonia (VAP) 4-item checklist
Three days after a patient is commenced on mechanical ventilation, are any of the following clinical items present?
WCC white cell count
a PaO2/FiO2 ratio: arterial oxygen tension divided by fraction of inspired oxygen
Item Definition
1 PaO2/FiO2  ratio
a ≤ 300 mmHg Deterioration in gas exchange over last 24 h in the absence of cardiogenic pulmonary oedema or pulmonary 
disease
2 Sputum changes A change in sputum characteristics, increased volume, or colour changes (yellow or green)
3 Chest X-ray infiltrates New localised or diffuse infiltrates on a single Chest X-ray (not explained by cardiogenic pulmonary oedema or 
pulmonary disease)
4 Inflammatory response ≥ 1 of the following (in the absence of immunocompromise)
 a ↑ Temperature New and persistent (last 24 h) elevated body temperature ≥ 38 °C (or > 37.5 °C if concurrent anti-pyretic medi-
cation administration)
 b WCC White cell count ≤ 4 or ≥ 12 cells  109/L for 2 days
 c ↑ Inflammation Elevated serum inflammatory markers: C-reactive Protein (> 100 mg/L) or Procalcitonin (> 2.5 ng/L) for a single 
blood test
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treating physicians appeared to diagnose VAP and 
prescribe antimicrobials based on clinical assessment, 
both independent of the clinical signs reflected in the 
VAP checklist and any available microbial reports.
While reports of sputum microbe isolates in patients 
classified with VAP in this cohort were sparse, a num-
ber of microbes associated with VAP were identified. 
Pseudomonas, Haemophilus, Methicillin sensitive 
Staphylococcus aureus (MSSA), Methicillin resistant 
Staphylococcus aureus (MRSA) and Escherichia coli are 
commonly reported in the literature [7]. Antimicrobial 
prescriptions were appropriate when sputum isolates 
were identified.
Prescribing practices may be influenced by different 
reporting practices and language in microbiological 
reporting. For example, laboratory reporting species-
level identification and/or antibiotic sensitivities may 
lead to increased antibiotic prescriptions. Also of note, 
antimicrobial prescription rates were 20% higher for 
patients with colonised sputum compared to infected 
sputum. It is known that many clinicians consider ‘colo-
nisation’ as the beginning of microbial infection; only 
a few consider colonisation and infection as different 
processes. It appears that physicians relied on their 
clinical judgement when prescribing antimicrobials.
Pulmonary infection accounted for just over half of 
all antimicrobial prescriptions in this sample; 10% lower 
than international estimates of the prevalence of infec-
tion types in ICU (64%) [8]. Given the study design, we 
were unable to examine physician considerations of fac-
tors known to affect treatment effectiveness (e.g. previous 
antimicrobial exposure; antibiogram for each setting). 
Considering local antibiograms is now highly recom-
mended when prescribing antimicrobials for nosocomial 
Table 2 Summary of audit findings
a Predominantly different sets of patients; five patients were classified with VAP using both methods
b All patients classified with VAP using both methods received antimicrobials
c Most frequently identified microbes: ‘Other Gram negatives’ and candida; ‘Pseudomonas sp.’; ‘Coagulase-negative staphylococcus’
Characteristic
Patient demographics (n = 169)
 Age (median—years) 59
 Sex—male (%) 65
 APACHE II (mean) 20.6
 Mechanical ventilation (median [IQR]—days) 7 [5–12]
 Length of stay (median—days)
  ICU 11
  Hospital 30
n/patient days Antimicrobial 
 prescribedb
n/patient 
days
VAP  identifieda
 Screening checklist 29/40 24 (83%)/34
 Independent physician diagnosis 29/67 27 (93%)/60
Sputum findings
 Colonisation 31/41 36/41 (88%)
 Infectionc 51/94 64/94 (68%)
  Screening checklist 13/13
  Independent physician diagnosis 9/10
Antimicrobial prescriptions %
Antibiotic 90
Antifungal 6
Indication for prescription (%) 80
 Clinically-diagnosed lung infection 54
 Prophylaxis 11
 Bloodstream infection 9
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pulmonary infections to reduce the incidence of resistant 
organisms [9].
The rate of antimicrobials prescribed as an apparent 
prophylaxis was high (11%), given that our inclusion cri-
teria likely excluded the majority of patients treated in 
ICU for postoperative care. The duration of treatment 
and types of antimicrobials (i.e. cefazolin and pipera-
cillin/tazobactam) prescribed for prophylaxis was of 
concern, given that a single only antimicrobial dose is 
recommended for the majority of surgeries. One possi-
ble explanation for this was the use of empiric therapy; 
physicians suspected, but could not confirm, a respira-
tory infection; or were attempting to prevent pneumonia 
within the setting of immunosuppression (we did not col-
lect data about immune status).
Importantly, while one in 10 prescriptions for prophy-
laxis is reflective of prescribing practices in Austral-
ian hospitals, this is double the target of 5% set by the 
national peak body [10]. This rate may however be 
reflective of prescribing practices in ICU, where rates 
are approximately twice those found in other hospi-
tal settings [10]. It would also appear that de-escalation 
of antimicrobial therapy was not extensively practiced, 
given the duration of broad spectrum antibiotic therapy. 
Prescription rates in Australia are among the highest in 
the developed World, so practices identified here may be 
reflective of overall health care practice in the country 
[10].
Antimicrobials were prescribed for more days for 
patients with a physician-diagnosis of VAP (compared 
to the VAP checklist). This is a logical finding, given that 
once a physician diagnosed (and documented) the pres-
ence of pneumonia, specific treatment would follow. 
Interestingly, the type of antimicrobial prescribed for 
patients with possible VAP using the screening checklist 
(e.g. Gram-negative antibiotics with anti-pseudomonal 
activity) suggested that treatment was focused on a pul-
monary infection.
Isolated sputum microbes were different for the two 
methods of VAP ‘diagnosis’ or ‘identification’ (noting that 
only five patients [17%] were classified using both meth-
ods). Given the small number of patients classified as 
having VAP, potential reasons for this variation cannot be 
elucidated; it is however unlikely that clinical differences 
such as patient ICU admission diagnosis and severity of 
illness were influencing factors [6].
This audit of 10 ICUs in Australia and New Zealand 
identified variations in antimicrobial prescribing prac-
tice in the context of VAP. Ordering of sputum microbial 
isolates was rare, and therefore the contribution of these 
reports to prescribing decisions was not evident, given 
the frequency of antimicrobial prescriptions for lung 
infection. It therefore appears that prescribing decisions 
were based on clinician suspicion of an infective lung 
process, and empiric therapy rather than the use of iden-
tified VAP criteria and guideline concordance. From an 
antimicrobial stewardship perspective, opportunities 
for reflections on and improvements in practice are evi-
dent, including reducing the prevalence of prescribing for 
prophylaxis, and de-escalation of antimicrobial treatment 
according to accepted practice guidelines and recent 
expert recommendations [3].
Limitations
From a methodological perspective, the audit design 
enabled sampling from multiple sites using a consist-
ent, standardised data collection approach. Most study 
ICUs were however large tertiary-referral units, poten-
tially limiting the representativeness of this sample to 
the broader ICU population, particularly for different 
countries and health systems. A limitation of using inde-
pendent assessors in data collection was that the real-
time, decision-making processes of physicians during 
their independent diagnosis of VAP and/or their anti-
microbial prescribing practices remains unknown. Our 
interpretations are therefore based on objective clinical 
diagnostic and microbiological data collected during the 
audit. We did not also collect data about the individual 
ICU contexts, specifically their antimicrobial policies 
(e.g. stewardship) and local antibiograms at the time data 
were collected.
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